Business Description
Bavarian Nordic AS
ISIN : DK0015998017
Description
Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora and Vivotif.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.57 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.06 | |||||
| Interest Coverage | 21.35 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 6.13 | |||||
| Beneish M-Score | -1.53 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 34.5 | |||||
| 3-Year EBITDA Growth Rate | 150.6 | |||||
| 3-Year Book Growth Rate | 11.5 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.06 | |||||
| 9-Day RSI | 42.59 | |||||
| 14-Day RSI | 45.59 | |||||
| 3-1 Month Momentum % | 13.81 | |||||
| 6-1 Month Momentum % | -9.7 | |||||
| 12-1 Month Momentum % | -0.61 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.81 | |||||
| Quick Ratio | 1.44 | |||||
| Cash Ratio | 0.68 | |||||
| Days Inventory | 262 | |||||
| Days Sales Outstanding | 59.7 | |||||
| Days Payable | 92.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.7 | |||||
| Shareholder Yield % | 1.96 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.9 | |||||
| Operating Margin % | 21.3 | |||||
| Net Margin % | 21.2 | |||||
| EBITDA Margin % | 32.29 | |||||
| FCF Margin % | -14.78 | |||||
| ROE % | 12.17 | |||||
| ROA % | 9.46 | |||||
| ROIC % | 11.87 | |||||
| 3-Year ROIIC % | 62.74 | |||||
| ROC (Joel Greenblatt) % | 46.97 | |||||
| ROCE % | 12.4 | |||||
| Years of Profitability over Past 10-Year | 6 | |||||
| Moat score | 6 | |||||
| Tariff score | 7 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 10.14 | |||||
| Forward PE Ratio | 10.28 | |||||
| PE Ratio without NRI | 10.18 | |||||
| Shiller PE Ratio | 115.96 | |||||
| PS Ratio | 2.16 | |||||
| PB Ratio | 1.14 | |||||
| Price-to-Tangible-Book | 2.46 | |||||
| Price-to-Operating-Cash-Flow | 11.88 | |||||
| EV-to-EBIT | 8.69 | |||||
| EV-to-Forward-EBIT | 5.16 | |||||
| EV-to-EBITDA | 5.94 | |||||
| EV-to-Revenue | 1.92 | |||||
| EV-to-Forward-Revenue | 1.13 | |||||
| EV-to-FCF | -13.1 | |||||
| Price-to-GF-Value | 0.84 | |||||
| Price-to-Median-PS-Value | 0.32 | |||||
| Price-to-Graham-Number | 1.05 | |||||
| Price-to-Net-Current-Asset-Value | 4.24 | |||||
| Earnings Yield (Greenblatt) % | 11.51 | |||||
| FCF Yield % | -7.05 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers